You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluconazole
Accession NumberDB00196  (APRD00327)
Typesmall molecule
Groupsapproved
Description

Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS. [PubChem]

Structure
Thumb
SynonymsNot Available
SaltsNot Available
Brand names
NameCompany
DiflucanNot Available
ElazorNot Available
FlucazolNot Available
FlucostatNot Available
FlunizolNot Available
MonicureNot Available
PritenzolNot Available
TricanNot Available
TriflucanNot Available
Brand mixturesNot Available
Categories
CAS number86386-73-4
WeightAverage: 306.2708
Monoisotopic: 306.104065446
Chemical FormulaC13H12F2N6O
InChI KeyRFHAOTPXVQNOHP-UHFFFAOYSA-N
InChI
InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
IUPAC Name
2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
SMILES
OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassBenzenoids
ClassBenzene and Substituted Derivatives
SubclassPhenylpropylamines
Direct parentPhenylpropylamines
Alternative parentsFluorobenzenes; Aryl Fluorides; Triazoles; Tertiary Alcohols; Polyamines; Organofluorides
Substituentsfluorobenzene; aryl halide; aryl fluoride; azole; tertiary alcohol; 1,2,4-triazole; polyamine; organohalogen; organofluoride; amine; alcohol; organonitrogen compound
Classification descriptionThis compound belongs to the phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
Pharmacology
IndicationFor the treatment of fungal infections.
PharmacodynamicsFluconazole, a synthetic antifungal agent of the imidazole class, is used to treat vaginal candidiasis. It inhibits the fungal lanosterol 14 alpha-demethylase which thereby prevents the formation of ergosterol which is an essential component in the fungal cell membrane.
Mechanism of actionFluconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Fluconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.
Absorption90%
Volume of distributionNot Available
Protein binding11 to 12%
Metabolism

Hepatic

Route of eliminationIn normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose appearing in the urine as unchanged drug.
Half life30 hours (range 20-50 hours)
Clearance
  • 0.23 mL/min/Kg [adults]
  • 0.18 mL/min/Kg [In premature newborns within 36 hours of birth]
  • 0.22 mL/min/Kg [In premature newborns 6 days old]
  • 0.33 mL/min/Kg [In premature newborns 12 days old]
  • 0.4 mL/min/kg [9 Months-13 yearsreceiving single-oral 2 mg/kg]
  • 0.51 mL/min/Kg [9 Months-13 yearsreceiving single-oral 8 mg/kg]
  • 0.49 mL/min/Kg [5-15 yearsreceiving multiple IV 2 mg/kg]
  • 0.59 mL/min/Kg [5-15 yearsreceiving multiple IV 4 mg/kg]
  • 0.66 mL/min/Kg [5-15 yearsreceiving multiple IV 8 mg/kg]
ToxicitySymptoms of overdose include hallucinations and paranoid behavior.
Affected organisms
  • Fungi
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9894
Blood Brain Barrier + 0.9382
Caco-2 permeable + 0.8867
P-glycoprotein substrate Non-substrate 0.6008
P-glycoprotein inhibitor I Non-inhibitor 0.8782
P-glycoprotein inhibitor II Non-inhibitor 0.9004
Renal organic cation transporter Non-inhibitor 0.6461
CYP450 2C9 substrate Non-substrate 0.7898
CYP450 2D6 substrate Non-substrate 0.9116
CYP450 3A4 substrate Non-substrate 0.565
CYP450 1A2 substrate Non-inhibitor 0.6312
CYP450 2C9 substrate Non-inhibitor 0.5497
CYP450 2D6 substrate Non-inhibitor 0.809
CYP450 2C19 substrate Inhibitor 0.532
CYP450 3A4 substrate Non-inhibitor 0.8196
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.524
Ames test Non AMES toxic 0.548
Carcinogenicity Non-carcinogens 0.7298
Biodegradation Not ready biodegradable 1.0
Rat acute toxicity 2.4136 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.8229
hERG inhibition (predictor II) Non-inhibitor 0.6614
Pharmacoeconomics
Manufacturers
  • Pfizer chemicals div pfizer inc
  • Aurobindo pharma usa inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Taro pharmaceutical industries ltd
  • Pfizer inc
  • Acs dobfar info sa
  • Apotex inc richmond hill
  • Hospira inc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hikma farmaceutica portugal lda
  • Teva parenteral medicines inc
  • Baxter healthcare corp
  • Bedford laboratories
  • Pfizer central research
  • Apotex inc
  • Aurobindo pharma ltd
  • Dr reddys laboratories inc
  • Gedeon richter usa inc
  • Genpharm inc
  • Glenmark generics ltd
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Unique pharmaceutical laboratories
Packagers
Dosage forms
FormRouteStrength
CapsuleOral
LiquidIntravenous
Powder, for solutionOral
SolutionIntravenous
TabletOral
Prices
Unit descriptionCostUnit
Diflucan 40 mg/ml Suspension 35ml Bottle203.65USDbottle
Fluconazole 40 mg/ml Suspension 35ml Bottle135.99USDbottle
Diflucan 10 mg/ml Suspension 35ml Bottle56.06USDbottle
Fluconazole 10 mg/ml Suspension 35ml Bottle35.94USDbottle
Diflucan 150 mg tablet24.71USDtablet
Diflucan 200 mg tablet20.82USDtablet
Diflucan 150 mg Capsule16.44USDcapsule
Fluconazole 200 mg tablet14.26USDtablet
Fluconazole powder14.08USDg
Fluconazole 150 mg tablet13.93USDtablet
Diflucan 100 mg tablet12.61USDtablet
Apo-Fluconazole-150 150 mg Capsule9.18USDcapsule
Co Fluconazole 150 mg Capsule9.18USDcapsule
Mylan-Fluconazole 150 mg Capsule9.18USDcapsule
Pms-Fluconazole 150 mg Capsule9.18USDcapsule
Fluconazole 100 mg tablet8.95USDtablet
Diflucan 50 mg tablet8.05USDtablet
Apo-Fluconazole 100 mg Tablet5.81USDtablet
Mylan-Fluconazole 100 mg Tablet5.81USDtablet
Fluconazole 50 mg tablet5.7USDtablet
Co Fluconazole 100 mg Tablet5.42USDtablet
Novo-Fluconazole 100 mg Tablet5.42USDtablet
Pms-Fluconazole 100 mg Tablet5.42USDtablet
Apo-Fluconazole 50 mg Tablet3.28USDtablet
Mylan-Fluconazole 50 mg Tablet3.28USDtablet
Co Fluconazole 50 mg Tablet3.06USDtablet
Novo-Fluconazole 50 mg Tablet3.06USDtablet
Pms-Fluconazole 50 mg Tablet3.06USDtablet
Diflucan-dextr 200 mg/100 ml1.28USDml
Diflucan-saline 200 mg/100 ml1.28USDml
Diflucan 2 mg/ml0.6USDml
Fluconazole 2 mg/ml0.33USDml
Fluconazole Omega 2 mg/ml0.33USDml
Fluconazole-dext 200 mg/100 ml0.32USDml
Fluconazole-ns 200 mg/100 ml0.19USDml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point138-140 °CNot Available
water solubility1 mg/LNot Available
logP0.4Not Available
Predicted Properties
PropertyValueSource
water solubility1.39e+00 g/lALOGPS
logP0.58ALOGPS
logP0.56ChemAxon
logS-2.3ALOGPS
pKa (strongest acidic)12.71ChemAxon
pKa (strongest basic)2.56ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count5ChemAxon
hydrogen donor count1ChemAxon
polar surface area81.65ChemAxon
rotatable bond count5ChemAxon
refractivity97.2ChemAxon
polarizability26.52ChemAxon
number of rings3ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterYesChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

DrugSyn.org

US4404216
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD00322
PubChem Compound3365
PubChem Substance46505735
ChemSpider3248
BindingDB25817
ChEBI46081
ChEMBLCHEMBL106
Therapeutic Targets DatabaseDAP000628
PharmGKBPA449653
HETTPF
Drug Product Database2245697
RxListhttp://www.rxlist.com/cgi/generic/flucon.htm
Drugs.comhttp://www.drugs.com/cdi/fluconazole.html
WikipediaFluconazole
ATC CodesD01AC15J02AC01
AHFS Codes
  • 08:14.08
PDB EntriesNot Available
FDA labelshow(16.9 KB)
MSDSshow(73.9 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolFluconazole may increase the serum concentration of acenocoumarol by decreasing its metabolism.
AlfentanilIncreases the effect and toxicity of alfentanil
AlprazolamFluconazole may increase the effect of the benzodiazepine, alprazolam.
AmitriptylineFluconazole may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
AnisindioneFluconazole may increase the serum concentration of anisindione by decreasing its metabolism.
ArtemetherAdditive QTc-prolongation may occur. Concomitant therapy should be avoided.
AtorvastatinIncreased risk of myopathy/rhabdomyolysis
BromazepamFluconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if fluconazole is initiated, discontinued or dose changed.
CarbamazepineFluconazole may increase the therapeutic and adverse effects of carbamazepine.
CarisoprodolStrong CYP2C19 inhibitors such as fluconazole may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
CelecoxibFluconazole may increase the effect of celecoxib.
ChlordiazepoxideFluconazole may increase the effect of the benzodiazepine, chlordiazepoxide.
CilostazolFluconazole may decrease the effect of cilostazol.
CisaprideIncreased risk of cardiotoxicity and arrhythmias
ClonazepamFluconazole may increase the effect of the benzodiazepine, clonazepam.
ClorazepateFluconazole may increase the effect of the benzodiazepine, clorazepate.
ConivaptanAntifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
CyclophosphamideFluconazole reduces metabolism and clearance of cyclophosphamide.
CyclosporineFluconazole may increase the therapeutic and adverse effects of the cyclosporine.
DiazepamFluconazole may increase the effect of the benzodiazepine, diazepam.
DicoumarolFluconazole may increase the serum concentration of dicumarol by decreasing its metabolism.
DihydroergotaminePossible ergotism and severe ischemia with this combination
EplerenoneThis CYP3A4 inhibitor increases the effect and toxicity of eplerenone
ErgotaminePossible ergotism and severe ischemia with this combination
EstazolamFluconazole may increase the effect of the benzodiazepine, estazolam.
EthotoinIncreases the effect of hydantoin
EverolimusFluconazole may increase everolimus levels/toxicity.
FentanylFluconazole may increase levels/toxicity of fentanyl.
FesoterodineFluconazole is a moderate CYP3A4 inhibitor thus reducing clearance. Monitor for adverse effects when using concomitant therapy with fesoterodine.
FlurazepamFluconazole may increase the effect of the benzodiazepine, flurazepam.
FluvastatinFluconazole may increase the serum concentration of fluvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fluvastatin if fluconazole is initiated, discontinued or dose changed.
FosphenytoinFluconazole may increase the effect of hydantoin.
HalazepamFluconazole may increase the effect of the benzodiazepine, halazepam.
HaloperidolFluconazole may increase the effect and toxicity of haloperidol.
ImipramineFluconazole may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of imipramine if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
IvacaftorModerate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction.
LovastatinIncreased risk of myopathy/rhabdomyolysis
LumefantrineAdditive QTc-prolongation may occur. Concomitant therapy should be avoided.
MephenytoinIncreases the effect of hydantoin
MidazolamFluconazole may increase the effect of the benzodiazepine, midazolam.
NortriptylineFluconazole may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
OspemifeneFluconazole, a moderate CYP3A / strong CYP2C9 / moderate CYP2C19 inhibitor, should not be used with ospemifene. Fluconazole increases the systemic exposure of ospemifene by 2.7-fold. Administration of fluconazole with ospemifene may increase the risk of adverse events.
PhenytoinFluconazole may increase the therapeutic and adverse effects of phenytoin.
PimozideIncreased risk of cardiotoxicity and arrhythmias
QuazepamFluconazole may increase the effect of the benzodiazepine, quazepam.
RamelteonFluconazole may increase the serum levels and toxcity of ramelteon.
RanolazineIncreased levels of ranolazine - risk of toxicity
RifabutinFluconazole may increase levels/toxicity of rifabutin.
RifampicinRifampin may decrease the effect of fluconazole.
SilodosinStrong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely.
SimvastatinIncreased risk of myopathy/rhabdomyolysis
TacrolimusAdditive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The antifungal, fluconazole, may also increase serum concentrations of tacrolimus.
TamoxifenFluconzole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluconazole is initiated, discontinued or dose changed.
TamsulosinFluconzole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluconazole is initiated, discontinued, or dose changed.
TerfenadineIncreased risk of cardiotoxicity and arrhythmias
ThiothixeneMay cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
TipranavirFluconazole may increase the serum concentration of Tipranavir. Dose adjustments are not required.
TofacitinibFluconazole (and other strong CYP2C19 inhibitors and moderate CYP3A4 inhibitors), when used in combination with tofacitinib, may increase tofacitinib concentration. It is recommended to modify therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5mg daily.
TolbutamideFluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Fluconazole therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed.
TolterodineFluconazole may decrease the metabolism and clearance of tolterodine. Adjust tolterodine dose and monitor for efficacy and toxicity.
TolvaptanFluconazole is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations
TorasemideFluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Fluconazole is initiated, discontinued or dose changed.
ToremifeneAdditive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
TramadolFluconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
TrazodoneThe CYP3A4 inhibitor, Fluconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fluconazole is initiated, discontinued or dose changed.
TriazolamFluconazole may increase the effect of the benzodiazepine, triazolam.
TrimethoprimThe strong CYP2C9 inhibitor, Fluconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluconazole is initiated, discontinued or dose changed.
TrimipramineAdditive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Fluconazole, a strong CYP2C19 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Concomitant therapy should be used with caution.
ValdecoxibFluconazole may increase the effect and toxicity of valdecoxib.
VerapamilFluconazole may increase the serum concentration of Verapamil by decreasing Verapamil metabolism. This likely occurs via Fluconazole-mediated CYP3A4 inhibition. Monitor for changes in the therapeutic/adverse effects of Verapamil if Fluconazole is initiated, discontinued, or dose changed.
VinblastineIncreases the effect and toxicity of anticancer agent
VincristineIncreases the effect and toxicity of anticancer agent
VoriconazoleFluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of voriconazole if fluconazole is initiated, discontinued or dose changed.
VorinostatAdditive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
WarfarinFluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluconazole is initiated, discontinued or dose changed.
ZafirlukastFluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluconazole is initiated, discontinued or dose changed.
ZiprasidoneAdditive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
ZolpidemFluconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if fluconazole is initiated, discontinued or dose changed.
ZuclopenthixolAdditive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Zuclopenthixol acetateAdditive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Zuclopenthixol decanoateAdditive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Food Interactions
  • Take without regard to meals.

Targets

1. Lanosterol 14-alpha demethylase

Kind: protein

Organism: Yeast

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Lanosterol 14-alpha demethylase P10613 Details

References:

  1. Bellamine A, Lepesheva GI, Waterman MR: Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology. J Lipid Res. 2004 Nov;45(11):2000-7. Epub 2004 Aug 16. Pubmed
  2. Guinea J, Sanchez-Somolinos M, Cuevas O, Pelaez T, Bouza E: Fluconazole resistance mechanisms in Candida krusei: the contribution of efflux-pumps. Med Mycol. 2006 Sep;44(6):575-8. Pubmed
  3. Chau AS, Chen G, McNicholas PM, Mann PA: Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae. Antimicrob Agents Chemother. 2006 Nov;50(11):3917-9. Epub 2006 Sep 11. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Niwa T, Shiraga T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005 Sep;28(9):1805-8. Pubmed
  2. Kunze KL, Wienkers LC, Thummel KE, Trager WF: Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos. 1996 Apr;24(4):414-21. Pubmed
  3. Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64. Pubmed
  4. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  6. Lexicomp.

2. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Niwa T, Shiraga T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005 Sep;28(9):1805-8. Pubmed
  2. Kunze KL, Wienkers LC, Thummel KE, Trager WF: Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos. 1996 Apr;24(4):414-21. Pubmed
  3. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  5. Lexicomp.

3. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Niwa T, Shiraga T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005 Sep;28(9):1805-8. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  3. Lexicomp.

4. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

5. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

6. Cytochrome P450 11B1, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 11B1, mitochondrial P15538 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW: Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002 Jan;46(1):160-5. Pubmed
  2. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. Pubmed
  3. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 08, 2013 14:23